Cibinetide (ARA-290)
Erythropoietin-derived 11-amino-acid peptide that selectively activates the EPO/CD131 tissue-protective receptor without raising hematocrit.
At a glance
What it is: Erythropoietin-derived 11-amino-acid peptide that selectively activates the EPO/CD131 tissue-protective receptor without raising hematocrit..
Primary research applications:
- Diabetic neuropathy and small-fiber neuropathy
- Sarcoidosis-associated neuropathy
- Tissue-protective applications under investigation
Editorial summary: Cibinetide is the most clinically advanced product in the "non-erythropoietic EPO" therapeutic concept — preserving erythropoietin's cytoprotective effects without its hematopoietic effect. Phase 2 results in sarcoidosis-associated small-fiber neuropathy and diabetic neuropathy have been favorable, and the molecule remains an instructive case study in receptor-selective peptide design.
- Class / structure
- 11-amino-acid peptide derived from erythropoietin's external loop
- Half-life
- Short systemic half-life; daily subcutaneous dosing in trials
- First described
- Mid-2000s (Brines and Cerami)
- Regulatory status
- Investigational
What is Cibinetide?
Cibinetide is a synthetic 11-amino-acid peptide that mimics the tissue-protective region of erythropoietin while lacking the structural elements responsible for hematopoietic effects.
Discovery and development
The cibinetide concept emerged from the work of Michael Brines and Anthony Cerami at the Kenneth S. Warren Institute, who showed that erythropoietin's tissue-protective effects (neuroprotection, cardioprotection, anti-inflammatory action) are mediated by a different receptor — the heteromeric EPO receptor / CD131 (β-common) complex — than its hematopoietic effects. Cibinetide is an 11-amino-acid peptide derived from EPO's external loop that selectively activates the tissue-protective receptor without raising red-cell mass.
Mechanism of action
Cibinetide binds the heteromeric EPO/CD131 receptor expressed on multiple non-erythroid tissues, activating cytoprotective signaling pathways including PI3K-Akt and JAK2-STAT5. The selectivity for the tissue-protective receptor over the classical EPOR homodimer (which drives hematopoiesis) is the engineering advance.[1]
Pharmacokinetics
Daily subcutaneous administration in trials. Plasma half-life is short, with the tissue-protective effects believed to be mediated through brief receptor engagement and downstream signaling.
What the research shows
The peer-reviewed literature on Cibinetide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Provides tissue protection without raising hematocrit | Mechanistic and clinical evidence | Supported |
| Improves small-fiber neuropathy in sarcoidosis | Phase 2 data favorable | Promising |
| Reverses diabetic neuropathy | Effects on biomarkers documented; clinical reversal not established | Mixed |
Reported user experiences
How the research describes administration
Phase 2 trials have used daily subcutaneous injection in courses of variable duration depending on the indication.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Cibinetide is a clean illustration of how selective receptor pharmacology can separate desirable from undesirable effects of an endogenous signaling system — preserving EPO's neuroprotective biology while avoiding its hematopoietic effect. Its clinical development has been incremental rather than transformative, but the conceptual contribution to receptor-selective peptide design is significant.
Frequently asked questions
Is cibinetide the same as erythropoietin (EPO)?
No. Cibinetide is a small peptide derived from EPO's external loop. It activates a different receptor — the heteromeric EPO/CD131 complex — than the EPOR homodimer that drives red-cell production. Cibinetide does not raise hematocrit.
References
- Brines M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A. 2008;105(31):10925-10930. https://pubmed.ncbi.nlm.nih.gov/18676614/
- Brines M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2014;20:658-666. https://pubmed.ncbi.nlm.nih.gov/25387363/